MetaVia EBITDA 2015-2024 | MTVA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

MetaVia ebitda from 2015 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

MetaVia ebitda from 2015 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$147B
Vertex Pharmaceuticals (VRTX)	$120.6B
Gilead Sciences (GILD)	$115.1B
Bristol Myers Squibb (BMY)	$114.9B
CSL (CSLLY)	$86.6B
Regeneron Pharmaceuticals (REGN)	$84.9B
GSK (GSK)	$71.4B
Argenex SE (ARGX)	$36.6B
Alnylam Pharmaceuticals (ALNY)	$32.8B
BioNTech SE (BNTX)	$28.4B
Illumina (ILMN)	$23.4B
Biogen (BIIB)	$22.9B
BeiGene (BGNE)	$18B
Moderna (MRNA)	$16.5B
Genmab (GMAB)	$14.3B
Incyte (INCY)	$14B
Insmed (INSM)	$13.3B
BioMarin Pharmaceutical (BMRN)	$12.6B
Bio-Techne Corp (TECH)	$12.2B
Sarepta Therapeutics (SRPT)	$12B
Exact Sciences (EXAS)	$11.7B
Vaxcyte (PCVX)	$11.3B
QIAGEN (QGEN)	$10.5B
Exelixis (EXEL)	$10.1B
Bio-Rad Laboratories (BIO.B)	$9.4B
Intra-Cellular Therapies (ITCI)	$8.9B
Roivant Sciences (ROIV)	$8.8B
Repligen (RGEN)	$8.7B
Ascendis Pharma (ASND)	$8.1B
Revolution Medicines (RVMD)	$7.8B